a study comparing the effect of two drugs namely sacubitril-valsartan and telmisartan in patients who get acute myocardial infarction or heart attack by seeing the effect of drugs on change in structure and functioning of heart muscles also known as remodelling seen using echocardiography as outcome

Sacubitril Valsartan versus Telmisartan in remodeling of left ventricleafter acute anterior wall myocardial infarction - NIL

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074343

Enrollment

160

Registered

2024-09-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I220- Subsequent ST elevation (STEMI) myocardial infarction of anterior wall Health Condition 2: I220- Subsequent ST elevation (STEMI) myocardial infarction of anterior wall

Interventions

Intervention1: drug name sacubitril valsartan: patients of anterior wall myocardial infarctin with heart failure will be divided into two groups. group A will be given sacubitril valsartan dose 50 mg

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 to 70 years. 2. Patients with Acute Anterior Wall Myocardial Infarction within past 7 days. undergoing coronary angiography. 3. Adequate echocardiographic image quality. 4. Availability of a follow-up evaluation at 6 and 12 months.

Exclusion criteria

Exclusion criteria: 1. Previous heart failure. 2. Renal dysfunction with eGFR of less than 60 ml per minute per 1.73 m2. 3. History of angioedema.

Design outcomes

Primary

Measure	Time frame
To monitor LV remodelling (i.e. increase in LVEDV by more than 20% occuring anytime over a period of one year) among the patients with AMI receiving sacubitril valsartan or telmisartan.Timepoint: To monitor LV remodelling (i.e. increase in LVEDV by more than 20% occuring anytime over a period of one year) among the patients with AMI receiving sacubitril valsartan or telmisartan. time points are 6 months and 12 months	—

Measure

Time frame

To monitor LV remodelling (i.e. increase in LVEDV by more than 20% occuring anytime over a period of one year) among the patients with AMI receiving sacubitril valsartan or telmisartan.Timepoint: To monitor LV remodelling (i.e. increase in LVEDV by more than 20% occuring anytime over a period of one year) among the patients with AMI receiving sacubitril valsartan or telmisartan. time points are 6 months and 12 months

—

Secondary

Measure	Time frame
To compare the changes in levels of cardiac biomarkers(Troponin I and BNP) among the patients with AMI receiving sacubitril valsartan or telmisartan at baseline, 6 months and after one year.Timepoint: To compare the changes in levels of cardiac biomarkers(Troponin I and BNP) among the patients with AMI receiving sacubitril valsartan or telmisartan at baseline, 6 months and after one year. time points are 6 months and 12 months	—

Measure

Time frame

To compare the changes in levels of cardiac biomarkers(Troponin I and BNP) among the patients with AMI receiving sacubitril valsartan or telmisartan at baseline, 6 months and after one year.Timepoint: To compare the changes in levels of cardiac biomarkers(Troponin I and BNP) among the patients with AMI receiving sacubitril valsartan or telmisartan at baseline, 6 months and after one year. time points are 6 months and 12 months

—

Countries

India

Contacts

Public ContactAmitoj singh sagoo

Government medical college and hospital

dramitojsingh7@gmail.com9888979319

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026